-+ 0.00%
-+ 0.00%
-+ 0.00%

Mizuho Maintains Outperform on Assembly Biosciences, Raises Price Target to $45

Benzinga·06/15/2026 17:17:47
Listen to the news
Mizuho analyst Salim Syed maintains Assembly Biosciences (NASDAQ:ASMB) with a Outperform and raises the price target from $40 to $45.